Changchun hi tech subsidiary's Baike biological herpes zoster live attenuated vaccine obtained clinical approval

Changchun hi tech announced on July 6 that the biological product "live attenuated herpes zoster vaccine" declared by Baike biology, the holding subsidiary of the company, has been approved for clinical application, and the company has obtained the product clinical approval documents, and will organize and implement clinical trials in accordance with the relevant requirements, including the safety and immunogenicity of the vaccine Live attenuated herpes zoster vaccine belongs to 6 categories of biological products for prevention, which is mainly used to prevent the occurrence of herpes zoster in the elderly At present, there are no similar varieties on the market in China The clinical approval document of this product was declared by BAC bio in May 2012 In April this year, Yang Zhanmin, chairman of Changchun hi tech, once said that the product is expected to obtain clinical approval and enter clinical trials this year, and said that more than 200 million elderly people in China are potential target population of the vaccine, and the target population for the company to declare indications is over 50 years old, with great market potential Baike biology is an important holding subsidiary of Changchun hi tech, which holds 46.15% of the shares It mainly produces varicella vaccine and rabies vaccine In 2013, the subsidiary realized an operating revenue of 286 million yuan, accounting for 14% of the total revenue of Changchun hi tech, and realized a net profit of 60.2031 million yuan, with a year-on-year increase of 114.08%.